WHO has sounded alarm over a sharp spike in HIV cases in the Philippines, Fiji and Papua New Guinea, urging urgent prevention ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

Gilead stock reversed its early losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes.

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

SINCE the 1980s, researchers have worked tirelessly to develop effective treatments that can suppress the HIV virus to ...

It found that across the 34 emergency departments taking part in the programme, 3,667 people were newly diagnosed with ...